BioCatalystWatch
NRXPWorkspace / NRXP / OverviewCompany library
NRX Pharmaceuticals, Inc. logo

NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. (NRXP)

Website

Price
Market cap
Next catalystFirst-in-human ALS trial targeted to commence in July 2027GNK-301 — planned first-in-human ALS trial · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

Cyclurad

NMDA receptor × D2 receptor × 5-HT2A receptor

IND

PreINDP1P2P3FilingApproved
Upcoming / outlook

Cyclurad

NMDA receptor × D2 receptor × 5-HT2A receptor

Upcoming / outlook

NRX-100

PreINDP1P2P3FilingApproved
Upcoming / outlook

NRX-200

Upcoming / outlook

GNK-301

HERV-K envelope protein

PreINDP2P3FilingApproved
Upcoming / outlook

Temelimab

HERV-W envelope protein

PreINDP1P2FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

NRX-100

PreINDP1P2P3FilingApproved
Upcoming / outlook

GNK-301

HERV-K envelope protein

PreINDP2P3FilingApproved
Upcoming / outlook

NRX-200

Upcoming / outlook

Temelimab

HERV-W envelope protein

PreINDP1P2FilingApproved
Upcoming / outlook

Cyclurad

NMDA receptor × D2 receptor × 5-HT2A receptor

IND

PreINDP1P2P3FilingApproved
Upcoming / outlook

Cyclurad

NMDA receptor × D2 receptor × 5-HT2A receptor

Upcoming / outlook

Other pipelines

Temelimab

HERV-W envelope protein

PreINDP1P2P3FilingApproved

Approved / commercial

NRX-100

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

History / paused

Temelimab

HERV-W envelope protein

PreINDP1P2P3FilingApproved
Temelimab

HERV-W envelope protein

PreINDP1P2P3FilingApproved
Temelimab

HERV-W envelope protein

PreINDP1P2P3FilingApproved

ACE2 × SARS-CoV-2 spike protein

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status
3M

Market Reaction / Supply Context

Market Structure

NRXP PR & News

NRXP SEC archive